Oncology and Hematology

Episodes 65-80 of 463

Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
Clinician's Roundtable
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
- Pedro Nascimento de Lima, PhD
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Project Oncology®
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
- Ryan Quigley
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
Project Oncology®
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Project Oncology®
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
- Brian Slomovitz, MD
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Project Oncology®
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
- Charles Turck, PharmD, BCPS, BCCCP
- Hope S. Rugo, MD, FASCO
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Project Oncology®
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
Project Oncology®
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
- Charles Turck, PharmD, BCPS, BCCCP
- Neil M. Iyengar, MD
- Komal Jhaveri, MD, FACP
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Project Oncology®
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
- Charles Turck, PharmD, BCPS, BCCCP
- Neil M. Iyengar, MD
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Project Oncology®
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
- Brian Slomovitz, MD
Putting Patients First: Personalized Care in Metastatic Breast Cancer
Putting Patients First: Personalized Care in Metastatic Breast Cancer
Global Oncology Academy
Putting Patients First: Personalized Care in Metastatic Breast Cancer
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19
Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19
Clinician's Roundtable
Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19
- Charles Turck, PharmD, BCPS, BCCCP
- Gloria Coronado, PhD
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Lunning, DO, FACP
MET and Other Emerging Targets in Metastatic NSCLC
MET and Other Emerging Targets in Metastatic NSCLC
MinuteCE®
MET and Other Emerging Targets in Metastatic NSCLC
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
MinuteCE®
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit